Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222652 | PMC |
| http://dx.doi.org/10.1016/j.jacc.2022.03.355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison in the adult congenital heart disease severity classification of ACC/AHA and ESC guidelines in a 3,459 Mexican population.
Int J Cardiol Congenit Heart Dis
March 2024
Surgical and Medical Cardiovascular Specialties Direction, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Background: Latin American registries of clinical and demographic profiles of ACHD are scarce. International guidelines classify disease complexity with different approaches. With these two regards, a registry was carried out to examine factors associated with mortality and to compare severity classifications in our population.
View Article and Find Full Text PDF[High blood pressure and associated lifestyles in an urban population in Argentina].
Medicina (B Aires)
December 2024
Escuela de Nutrición, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Introduction: The American Heart Association (AHA/ACC) sets as a goal for blood pressure (BP) control not to exceed values of 130/80 mmHg, both in individuals with and without a diagnosis of hypertension (HT), standards not evaluated so far in the Argentine population. The objective was to determine the prevalence of high BP (HBP) in individuals with and without a diagnosis of HT taking into account the AHA/ACC criteria and to evaluate its association with sociodemographic and lifestyle factors.
Materials And Methods: Cross-sectional populationbased study in 911 persons >18 years of age in Córdoba, Argentina (period 2020-2022).
New and future heart failure drugs.
Nat Cardiovasc Res
December 2024
Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
In the past decade, our understanding of heart failure pathophysiology has advanced significantly, resulting in the development of new medications such as angiotensin-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors and oral soluble guanylate cyclase stimulators. Backed by positive findings from large randomized controlled trials, recommendations for their use were recently included in the 2022 AHA/ACC/HFSA guidelines and 2023 ESC guidelines for management of heart failure. Promising drugs for future heart failure treatment include agents that modulate the neurohormonal system, vasodilators, anti-inflammatory drugs, mitotropes, which improve deranged energy metabolism of the failing heart, and myotropes, which increase cardiac contractility by affecting cardiac sarcomere function.
View Article and Find Full Text PDFAngiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting.
Ann Pharmacother
November 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
Background: The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi). The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema. This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.
View Article and Find Full Text PDFArticle Synopsis
- The "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery" provides updated recommendations for clinicians to evaluate and manage the cardiovascular health of adult patients undergoing noncardiac surgeries.
- A comprehensive literature search was conducted from August 2022 to March 2023 to gather relevant clinical studies and reviews published in English, ensuring the guidelines are evidence-based.
- The new guideline replaces the older 2014 version, incorporating updated findings and offering specific strategies for managing cardiovascular disease during the perioperative period, including medication and monitoring techniques.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!